Updated:
Opko Health
Opko Health is a healthcare company with headquarters in Miami, Florida and operations in New York and Chicago. The firm structures itself as a...
Opko Health
Opko Health is a healthcare company with headquarters in Miami, Florida and operations in New York and Chicago. The firm structures itself as a fully-integrated healthcare business spanning drug development, diagnostics, and partnerships. The firm's core business lines include marketed therapies (NGENLA, a Pfizer-partnered growth hormone treatment approved in over 40 markets), a clinical diagnostics unit (BioReference Laboratories, serving about 11 million patients annually), and a research pipeline focused on multispecific therapies for cancers and infectious disease. Opko's R&D team includes former leaders of N.I.H. and Sanofi. The firm has attracted partnerships with Merck, N.I.H., and BARDA. Opko Health reports no public AUM or deployment figures. Its team size is undisclosed. The firm maintains additional offices in New York and Chicago. In 2026, ModeX Therapeutics (a subsidiary) presented preclinical data on in vivo CAR-T cell generation — a recent operational indicator of R&D progress. The firm's structural differentiator is its vertically-integrated model: it operates as both a pharmaceutical developer and a large-scale clinical reference lab, which provides a platform for real-world evidence generation and potential pipeline synergies between diagnostics and therapeutics.
General information
Firm type
other
Year founded
—
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Miami
Corporate office
4400 Biscayne Boulevard, Miami, FL 33137, United States
Additional offices
New York, NY, United States · Chicago, IL, United States
Sector focus
Frequently asked questions
Who runs investment decisions at Opko Health?
Opko Health is a publicly-traded company (NYSE: OPK). Investment decisions are governed by its board of directors and executive management team, whose backgrounds include leadership roles at N.I.H. and Sanofi (per company website).
How is Opko Health structured — as a family office or a healthcare company?
Opko Health is a fully-integrated healthcare company, not a family office. It operates BioReference Laboratories (a clinical reference lab), develops and markets pharmaceutical therapies, and conducts R&D in multispecific medicine. Its stock is publicly traded.
Does Opko Health manage assets for outside investors?
No. Opko Health is a public company that raises capital through equity and debt markets. It does not manage third-party assets in a family office capacity.
What are Opko Health's primary revenue sources?
Opko Health generates revenue through pharmaceutical sales (NGENLA partnered with Pfizer, and RAYALDEE), diagnostic services via BioReference Laboratories, and government/partner funding for R&D programs.
Who are Opko Health's key partners?
Opko Health partners with Pfizer on NGENLA (marketed in over 40 countries), Merck on R&D programs, the N.I.H., and BARDA. These partnerships are disclosed on the company's website.
What therapeutic areas does Opko Health focus on?
Opko Health focuses on serious diseases including pediatric growth hormone deficiency (NGENLA), secondary hyperparathyroidism (RAYALDEE), cancers, and infectious diseases through its multispecific research platform.
Does Opko Health operate internationally?
Yes. NGENLA is approved in over 40 markets worldwide. The firm's partnerships with Pfizer and other global organizations facilitate international distribution of its therapies.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on investors?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: